Knowledge Library
BTK Inhibitor-Resistant Lymphoma Animal Models
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use of BTK inhibitors, have significantly improved the care of patients with CLL. However, over time, many patients develop resistance to these drugs. Acquired resistance to the BTK inhibitor ibrutinib is mediated by the C481S mutation, …Read More >
TLR8 Mouse Model to Evaluate anti-HBV Agents
Toll-like receptor 8 (TLR8) plays an essential role in human antiviral immunity by recognizing ssRNA of viruses. Upon activation by specific ligands, TLR8 can trigger potent antiviral responses. Development of an in vivo preclinical model has the potential to greatly accelerate research focused on new anti-HBV agents. However, rodent TLR8 is unresponsive to human TLR8 …Read More >
Oncogenic Virus-associated Tumor Models
Viruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily from viruses like HPV, EBV, HBV, and HCV. The innate and adaptive immune systems play important roles in oncogenic viral infection and subsequent cancer development. As viral cancers have viral-specific targets and biomarkers, there is …Read More >
Pulmonary Disease Platform
WuXi AppTec offers a comprehensive platform of pulmonary disease-related services. We provide a wide panel of validated disease models, including pulmonary fibrosis, pulmonary arterial hypertension, asthma, and chronic obstructive pulmonary disease. Our experts utilize advanced technologies with fully equipped invasive and non-invasive systems, such as the pulmonary function test system.
OncoWuXi Express: PDX Panel Service
OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share our newly launched PDX panel service with you. https://onco.wuxiapptec.com Introduction: Patient-derived xenograft (PDX) models are generated by implanting …Read More >
OncoWuXi Express: Efficacy of JAK Inhibitors in a Type II Collagen-induced Arthritis Model
Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we present an evaluation of the efficacy of different JAK subtype inhibitors in a Type II collagen-induced arthritis model, along with corresponding …Read More >
USP7 Inhibitors Reveal a Differentiated Mechanism of p53-Driven Anti-Cancer Activity
Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that cleaves ubiquitin from a range of substrates, shielding them from degradation by the proteasome. USP7 activity has been implicated in cancer progression and its overexpression is associated with tumor aggressiveness and poor prognosis in a variety of cancer types, making USP7 inhibition an attractive strategy for …Read More >
Paclitaxel-Induced Resistant Tumor Models
Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. WuXi Biology has established gastric cancer and breast cancer cell lines that …Read More >
In Vivo Pharmacology for Ophthalmic Drug Development
Introduction The number of people with vision impairment has increased due to the continuously expanding and aging population, as well as lifestyle changes. According to the Lancet Global Health, by 2050, myopia is expected to affect 5 billion people. Additionally, the number of individuals with distance vision impairment is projected to reach 895 million, including …Read More >